Datamonitor's October edition of the Infectious Diseases Review brings you the latest news, expert analysis and research in the infectious diseases market.

It covers all the major current business issues and events, including R&D, licensing deals, alliances and joint ventures, and regulatory decisions.

Scope

• Strategic insight into the future shape of infectious diseases companies and markets

• The most significant infectious diseases news compiled into one monthly update

• Expert analysis into the implications of the month's important events in infectious diseases

• Insight into the future shape of the market for players at all levels

• All the month's infectious diseases stories in headline and summary form

Report Highlights

Out of the dozens of topics covered in this month's review, the most important include:

* The Immune Response Corporation released results from an ongoing Canadian study, which gave the first indication in clinical trials that Remune might give relief for HIV-infected patients from the adverse side-effects of antiretroviral therapies.

* GlaxoSmithKline launched a lawsuit against a Novartis subsidiary that manufactures a generic version of its antibiotic Augmentin. GlaxoSmithKline claims the generic version is based on a type of bacteria stolen by a former employee.

Reasons to Purchase

• Not only keeps you updated about industry events - it also gives you opinion and insight

• Draws upon Datamonitor analysts' extensive experience to bring you our perspective on the impact of the latest events

• Provides you with your own news archive to track company and industry progress, giving you an extensive reference to relevant events and issues

R&D UPDATE: HIV

The most significant news in HIV R&D, compiled into one monthly update.

R&D UPDATE: HEPATITIS

The most significant news in hepatitis R&D, compiled into one monthly update.

R&D UPDATE: BACTERIAL INFECTIONS

The most significant news in bacterial infections R&D, compiled into one monthly update.

R&D UPDATE: FUNGAL INFECTIONS

The most significant news in fungal infections R&D, compiled into one monthly update.

R&D UPDATE: OTHER INFECTIOUS

The most significant news in other infectious R&D, compiled into one monthly update including:

• Malaria

• Smallpox

LATEST COMMENT

Expert analysis of the implications of the month's important industry events

• Cipla: lobbying for more generics in South Africa

• Alternative therapies: hurting HIV regimes

• HIV treatment: non-compliance brings pitfalls without benefits

• Lilly: no European rebirth for Xigris

• Bayer: seeking Gamunex approval

FEATURE ANALYSIS

Analyst-written feature articles, featuring the latest insights into the industry

• HIV: the crisis continues

NEWS HEADLINES - HIV

All the month's HIV news stories in headline and summary form

NEWS HEADLINES - HEPATITIS

All the month's hepatitis news stories in headline and summary form

NEWS HEADLINES - BACTERIAL INFECTIONS

All the month's bacterial infections news stories in headline and summary form

NEWS HEADLINES - FUNGAL INFECTIONS

All the month's fungal infections news stories in headline and summary form

NEWS HEADLINES - OTHER INFECTIOUS

All the month's other infectious news stories in headline and summary form.

To order - click here!